A comparison study of dynamic [18F]Alfatide II imaging and [11C]MET in orthotopic rat models of glioblastoma

• Published in: Journal of cancer research and clinical oncology Vol. 150; no. 4; p. 208
• Main Authors: Pan, Yue, Dang, Haodan, Zhou, Haoxi, Fu, Huaping, Wu, Shina, Liu, Huanhuan, Zhang, Jinming, Wang, Ruimin, Tian, Yuan, Xu, Baixuan
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 22.04.2024; Springer Nature B.V
• Subjects: Animal models; Animals; Brain Neoplasms - diagnostic imaging; Brain Neoplasms - metabolism; Brain Neoplasms - pathology; Brain tumors; Cancer Research; Carbon Radioisotopes; Cell Line, Tumor; Disease Models, Animal; Fluorine Radioisotopes; Glioblastoma; Glioblastoma - diagnostic imaging; Glioblastoma - metabolism; Glioblastoma - pathology; Glioma; Glioma cells; Hematology; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Methionine; Methionine - pharmacokinetics; Neuroimaging; Oncology; Peptides, Cyclic - pharmacokinetics; Pharmacokinetics; Positron emission tomography; Positron-Emission Tomography - methods; Radiopharmaceuticals - pharmacokinetics; Rats; Vascularization; Western blotting; C]Methionine; C]MET; F]Alfatide II; Positron emission tomography (PET); [; Glioblastoma multiforme (GBM); [11C]Methionine([11C]MET); [18F]Alfatide II
• ISSN: 1432-1335; 0171-5216; 1432-1335
• DOI: 10.1007/s00432-024-05688-4

Purpose To investigate and compare the dynamic positron emission tomography (PET) imaging with [ 18 F]Alfatide II Imaging and [ 11 C]Methionine ([ 11 C]MET) in orthotopic rat models of glioblastoma multiforme (GBM), and to assess the utility of [ 18 F]Alfatide II in detecting and evaluating neoangiogenesis in GBM. Methods [ 18 F]Alfatide II and [ 11 C]MET were injected into the orthotopic GBM rat models ( n  = 20, C6 glioma cells), followed by dynamic PET/MR scans 21 days after surgery of tumor implantation. On the PET image with both radiotracers, the MRI-based volume-of-interest (VOI) was manually delineated encompassing glioblastoma. Time-activity curves were expressed as tumor-to-normal brain ratio (TNR) parameters and PET pharmacokinetic modeling (PKM) performed using 2-tissue-compartment models (2TCM). Immunofluorescent staining (IFS), western blotting and blocking experiment of tumor tissue were performed for the validation. Results Compared to 11 C-MET, [ 18 F]Alfatide II presented a persistent accumulation in the tumor, albeit with a slightly lower SUVmean of 0.79 ± 0.25, and a reduced uptake in the contralateral normal brain tissue, respectively. This resulted in a markedly higher tumor-to-normal brain ratio (TNR) of 18.22 ± 1.91. The time–activity curve (TACs) showed a significant increase in radioactive uptake in tumor tissue, followed by a plateau phase up to 60 min for [ 18 F]Alfatide II (time to peak:255 s) and 40 min for [ 11 C]MET (time to peak:135 s) post injection. PKM confirmed significantly higher K 1 (0.23/0.07) and K 3 (0.26/0.09) in the tumor region compared to the normal brain with [ 18 F]Alfatide II. Compared to [ 11 C]MET imaging, PKM confirmed both significantly higher K 1 /K 2 (1.24 ± 0.79/1.05 ± 0.39) and K 3 /K 4 (11.93 ± 4.28/3.89 ± 1.29) in the tumor region with [ 18 F]Alfatide II. IFS confirmed significant expression of integrin and tumor vascularization in tumor region. Conclusion [ 18 F]Alfatide II demonstrates potential in imaging tumor-associated neovascularization in the context of glioblastoma multiforme (GBM), suggesting its utility as a tool for further exploration in neovascular characterization.